SINGAPORE, April 26, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company), a leading global medical technology company, has launched a new patient safety program for hospitals, called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME). Aimed at addressing the top two challenges in a hospital setting – infection prevention and medication safety – PRIME is developed by Joint Commission International for Patient Safety, with sponsorship by BD.
(L-R) Program logo of the PRIME program; BD & JCI representatives along with guests from leading private hospitals in the region at the PRIME launch ceremony for SEA held in Bangkok, Thailand on 24th April 2019.
Speaking about JCI’s initiation of PRIME with BD, Dr. Marwa J. Zohdy, vice president, Global Consulting Services, Joint Commission Resources/Joint Commission International (JCI) said, "The preparation and administration of medication is critical to safe, high-quality patient care around the world. At JCI, we recognize a fundamental need for evidence-based capability building on this topic, and the unique PRIME program addresses that need. Leading experts from JCI with the support of BD have created a practical curriculum that will bring critical skills to life."
A unique programmatic approach towards patient safety will be implemented over a six-month duration, composed of goal-setting, constant progress review, tele-consultations with experts and scientific updates through webinars. Hospitals will be certified upon successful completion of the program.
Raymond Chow, vice president for Central Asia at BD said, "Administration of medication via invasive routes presents unique risks. Particularly in emerging countries, the risks may be greater due to lack of awareness, standards, assessment of skills and adoption of safe technology and practices. PRIME is set to address these very risks that are often unnoticed due to inadequate focus or knowledge of streamlined processes in medication management."
PRIME was officially launched between 22-26 April in the following countries: South Korea, Japan, Malaysia, Thailand, Indonesia, Philippines, Vietnam and India. To date, 21 leading hospitals have signed up for the program.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.
Photo – https://photos.prnasia.com/prnh/20190425/2446684-1 Logo – https://photos.prnasia.com/prnh/20190425/2446684-1LOGO Related Links :http://www.bd.com/